

RECEIVED
FEB 08 2002

TECH CENTER 1600/2900

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
55669-Z/JPW/BJA

Serial No.
09/832,648

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants
Cy A. Stein

Filing Date
April 11, 2001

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JG	US 5 0 2 3 2 4 3	6/11/91	Tullis, R.			
	US 5 1 0 7 0 6 5	4/21/92	Schewmaker, et al.			
	US 5 5 8 7 4 7 0	12/24/96	Cook, et al.			
	US 5 6 7 0 6 3 3	8/23/97	Cook, et al.			
	US 5 7 3 4 0 3 3	3/31/98	Reed, J.			
	US 5 8 4 3 7 1 3	12/1998	Yoshida et al.			
	US 5 7 7 6 9 0 5	7/1998	Gibbons et al.			
	US 5 7 0 2 8 9 7	12/1997	Reed et al.			
	US 5 4 9 6 5 4 7	3/1996	Lam et al.			
	US 5 5 9 3 9 7 4	1/1997	Rosenberg et al.			

RECEIVED

FEB 08 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
9 8 0 5 7 7 7	2/1998	WO			
9 5 1 5 4 0 0	6/1995	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Agrawal, S., et al., <u>Proc. Natl. Acad. Sci. U.S.A.</u> (1988) Vol. 85:7079-7083;
Beaucage, S., and Caruthers, M., <u>Tetrahedron Lett.</u> (1981) Vol. 22:1859-1862;
Cook, P.D., "Medicinal Chemistry of Antisense Oligonucleotides - future opportunities" (1991) <u>Anti Cancer Drug Design</u> Vol.

EXAMINER

DATE CONSIDERED

2-23-04

*EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Applicants: Cy A. Stein
U.S. Serial No.: 09/832,648
Filed: April 11, 2001
Exhibit A

RECEIVED

FEB 0 8 2002

Sheet 2 of 3

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICETECH CENTER 1600/2900
SERIAL NO.
55669-Z/JPW/BJA 09/832,648INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)APPLICANT
Cy A. SteinFILING DATE
April 11, 2001

GROUP ART UNIT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RECEIVED

FEB 0 8 2002

TECH CENTER 1600/2900


8:585-607;

Ghosh, S., et al., J. Biol. Chem. (1990) Vol. 265:2935-2940;Hemken, P., et al., J. Biol. Chem. (1992) Vol. 267:9948-0057;Iverson, P., Anti-Cancer Drug Des. (1991) Vol. 6:531-538;Krajewska, M. et al. "Immunohistochemical analysis bcl-2, bax, bcl-x,
and mcl-1 expression in prostate cancer." Am. J. Pathol. (1996) Vol.
148:1567-1576;Luedeke, G.H., Ziegler, Al., Stahel, R.A., and Zangemeister-Wittke,
U., "Antisense oligonucleotides targeting sequences shared by the
Bcl-2 and the Bcl-xL mRNA efficiently downregulate expression of
both proteins and induce apoptosis of lung cancer cells." Division
of Oncology, Department of Internal Medicine, University Hospital,
CH-8091 Zurich, Switzerland. (Abstract #1140 from 88 Ann. Meet.
AACR, April 12-16, 1997, Vol. 38, (March 1997), p. 171);Milligan et al., "Current Concepts in Antisense Drug Design," Journal
of Medicinal Chemistry (July 9, 1993) Vol. 36:1924-1937;Pollman et al., "Inhibition of neointimal cell bcl-x expression
induces apoptosis and regression of vascular disease," Nature
Medicine (1998) Vol. 4:222-227 (Exhibit 15);Ratajczak, et al., Proc. Natl. Acad. Sci. U.S.A. (1992) Vol.
89:11823;Stein, C. et al., Pharmac. Ther. (1991) Vol. 52:365-384;Uhlmann, E. And Peyman A., "Antisense Oligonucleotides: A New
Therapeutic Principle" Chem. Rev. (1990) Vol. 90:544-579;

EXAMINER

DATE CONSIDERED

*EXAMINER: initial if citation considered whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 55669-Z/JPW/BJA	SERIAL NO. 09/832,648
		INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	
		APPLICANT Cy A. Stein	
		FILING DATE April 11, 2001	GROUP ART UNIT
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Wang, Z. et al., "Induction of bcl-x1 by CD40 Engagement Rescues slg-induced Apoptosis in Murine B Cells", <u>The Journal of Immunology</u> (1995) Vol. 155:3722-3725;		
	Zhao, Q., et al., <u>Antisense Research and Development</u> (1993) Vol. 3:53-66;		
	Zon, G., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," <u>Pharmaceutical Research</u> (November 9, 1988) Vol. 5:539-549;		
	"Antisense 1997: A roundtable on the state of the industry" (1997) <u>Nature Biotechnology</u> . 15:519-524;		
	Crooke, S.T., "Vitravene - Another piece of the Mosaic". (1998) <u>Antisense and Nucleic Acid Drug. Dev.</u> 8:vii-viii;		
	Gewritz et al. "Facilitating oligonucleotide delivery: helping antisense deliver on its promise" (1996) <u>PNAS</u> 93:3161-3163;		
	Gura, T. "Antisense has growing pains" (1995) <u>Science</u> 270:575-577;		
	Stein C.A. "Keeping the Biotechnology of antisense in context" (1999) <u>Nature Biotechnology</u> 17:209;		
	Stull et al. "Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects" (1995) <u>Pharm. Res.</u> 12:465-483;		
	Rojanasakul, Y. "Antisense oligonucleotide therapeutics: Drug delivery and targeting" (1996) <u>Adv. Drug Delivery Rev.</u> 18:115-131.		
EXAMINER	DATE CONSIDERED		
<i>East. Lep. Ind</i>	2-25-04		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED

FEB 08 2002

TECH CENTER 1600/2900